Fig. 4: HIPK2 is the target gene of miR-221-3p in MCF-7/ADR cells. | Experimental & Molecular Medicine

Fig. 4: HIPK2 is the target gene of miR-221-3p in MCF-7/ADR cells.

From: METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner

Fig. 4

a Twenty common putative target genes of miR-221-3p among the miRWalk (http://mirwalk.umm.uni-heidelberg.de/), RAID (http://www.rna-society.org/raid2/index.html), TargetScan (http://www.targetscan.org/vert_71/), DIANA TOOLS (http://diana.imis.athena-innovation.gr/DianaTools/), mirDIP (http://ophid.utoronto.ca/mirDIP/) and starBase (http://starbase.sysu.edu.cn/) databases, shown by Venn diagram. b Twenty putative target genes of miR-221-3p mapped into the GeneMANIA database (http://genemania.org/), with a constructed PPI network. c The miR-221-3p binding sites in the 3′UTR of HIPK2 by TargetScan database analysis. d Correlation between miR-221 and HIPK2 in BC predicted by LinkedOmics from TCGA database (Cor = −0.1462, p = 5.663E−05). e Immunoblots and quantification of HIPK2 among MCF-10A human breast epithelial cells, MCF-7/ADR cells, and MCF-7/S cells. f miR-221-3p binding with HIPK2 verified by the luciferase reporter assay. g Immunoblots and quantification of HIPK2 in MCF-7/ADR cells treated with expression vector containing the METTL3 and/or miR-221-3p-specific inhibitor, normalized to GAPDH. Statistical comparisons were performed using unpaired t-test when only two groups were compared or by Tukey’s test-corrected ANOVA when more than two groups were compared. *p < 0.05 compared to MCF-10A, NC mimic, or empty vector (oe-NC) + NC inhibitor and #p < 0.05 compared to MCF-7/S cells or expression vector containing the METTL3 + NC inhibitor.

Back to article page